体外膜肺氧合作为严重肺动脉高压肺移植桥接
单中心回顾性研究评估严重肺动脉高压患者肺移植前使用ECMO桥接的结局。123例列表中114例接受肺移植,28例需ECMO桥接;桥接组原发移植物功能障碍3级与移植物生存无差异,但ICU住院更长、再开胸与血管并发症更多。
要点
- ECMO桥接未影响严重PH肺移植的移植物生存。
- 桥接组术后ICU住院时间更长,再开胸和血管并发症更多。
- NT-proBNP、6分钟步行距离和静息氧需求与90天内ECMO桥接风险相关。
核心结论
- 严重PH患者肺移植生存结局不受ECMO桥接影响,但桥接增加额外风险。
- 应鼓励采用易测量参数预先识别需桥接患者以辅助有效分配。
研究设计与样本
- 单中心回顾性研究,纳入2010年1月至2023年3月列表等待肺移植的PH患者。
- 123例列表中114例接受肺移植,其中28例需要ECMO桥接。
- 按ECMO桥接状态比较围术期与术后病程。
- 桥接风险分析纳入列表时未需ECMO者,评估90天内再评估时的列表参数,采用单因素Cox比例风险回归。
主要发现
- 72小时原发移植物功能障碍3级:桥接组30% vs 非桥接组20%,P=0.28。
- 移植物生存:1年82% vs 88%,5年54% vs 59%,P=0.84。
- ECMO桥接导致移植后ICU住院时间更长(P=0.002)。
- 再开胸(P=0.049)与血管并发症(P=0.031)在桥接组更高。
关键数值与推荐
- 增加90天ECMO风险的 factors:N末端B型利钠肽原(P<0.001)、6分钟步行距离(P=0.03)、静息氧需求(P=0.006)。
临床怎么用
- 严重PH肺移植前ECMO桥接不损害移植物生存,但需权衡ICU住院延长及再开胸、血管并发症风险。
- 可关注NT-proBNP、6分钟步行距离和静息氧需求以早期识别可能需要桥接的患者。
局限性
- 单中心回顾性研究,样本量有限,桥接组仅28例。
- 桥接风险分析为单因素Cox回归,未报告多因素校正结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe pulmonary hypertension (PH) is the leading indication for a lung transplant in younger patients. Despite the availability of validated risk scores, their influence on lung allocation has been negligible, with continued reliance on decompensation and bridging with extracorporeal membrane oxygenation (ECMO).This single-centre, retrospective study assessed outcome of ECMO bridging in lung transplant for PH and evaluated short-term predictability of ECMO bridging. METHODS: Patients with PH listed for a lung transplant between January 2010 and March 2023 were included. Peri- and postoperative courses were compared dependent upon ECMO bridging status. Bridging risk analysis within 90 days of re-evaluation included patients not requiring ECMO at listing, with listing parameters evaluated using a univariate Cox proportional hazard regression. RESULTS: A total of 114/123 patients listed underwent lung transplant. Twenty-eight required ECMO bridging. No differences in primary graft dysfunction grade 3 at 72 h (30 vs 20%; P = 0.28) or graft survival (1 year: 82 vs 88%; 5 years: 54 vs 59%; P = 0.84) were evident. ECMO bridging resulted in longer intensive care unit stays post-transplant (P = 0.002) and higher rates of both re-thoracotomy (P = 0.049) and vascular complications (P = 0.031). Factors increasing 90-day ECMO risk included N-terminal pro-B-type natriuretic peptide (P < 0.001), 6-min walk distance (P = 0.03) and O2 requirement at rest (P = 0.006). CONCLUSIONS: Lung transplant survival outcomes are not affected by ECMO bridging in patients with severe PH. It does, however, expose patients to additional risk, and efforts such as easy-to-measure parameters to pre-emptively identify patients requiring bridging to assist with effective allocation should be encouraged.
引用
- Kruszona S, Aburahma K, Wand P, et al. Extracorporeal membrane oxygenation as a bridge to transplant in severe pulmonary hypertension. Eur J Cardiothorac Surg. 2024. PMID: 39626308. doi:10.1093/ejcts/ezae420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。